# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.26) per share. This is a 38.1 percent increase over losses of ...
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $...
Senti Biosciences, Inc. (NASDAQ:SNTI) (“Senti Bio” or the “Company”), a clinical stage biotechnology company developing next-ge...